IP Library › Granted Patent US 9,709,565
Granted Patent B2
US 9,709,565 · App. 13/090,893 · Granted Jul 18, 2017

Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof

Inventors: Eran Eden (Haifa, IL); Kfir Oved (Hof HaCarmel, IL)
Assignee: MeMed Diagnostics Ltd.
G01N33/56983A61K45/06G01N33/569G01N33/56911G01N2333/4737G01N2333/914
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,709,565
App. No.
13/090,893
Granted
Jul 18, 2017
Kind
B2
Abstract

The present invention provides methods of detecting infection using biomarkers. The methods disclosed herein include measuring the expression level of one of more polypeptide determinant in which the alteration of the expression level indicates infection of the patient in a sample of the subject and determining a clinically significant alteration in the level of the one or more polypeptides in the sample, wherein the alteration indicates an infection in the subject. The methods provided herein are for distinguishing between bacterial infection, mixed infection and/or viral infection.

Claims (16)

1. A method of diagnosing and treating a bacterial infection in a subject comprising:

a) contacting a blood sample with an RSAD2 antibody under conditions which allow binding of said RSAD2 antibody to RSAD2 of the cell;

b) measuring the amount of said RSAD2 antibody which is bound to RSAD2 in said blood sample to determine the RSAD2 expression level;

c) comparing the RSAD2 expression level to a predetermined reference value;

d) classifying the subject as having a bacterial infection or a mixed co-infection according to the results of the comparing; and

e) treating the subject classified as having said bacterial infection or said mixed co-infection with an antibiotic.

2. The method of claim 1 , wherein said reference value is an index value.

3. The method of claim 1 , further comprising measuring one or more non-polypeptide determinants selected from the group consisting of white blood count, neutrophil percent, lymphocyte percent, monocyte percent, absolute lymphocyte count, absolute neutrophil count and maximimal temperature.

4. The method of claim 1 , further comprising measuring the expression level of a determinant selected from the group consisting of CRP and MX1.

5. The method of claim 1 , wherein the sample is whole blood.

6. The method of claim 1 , wherein the sample is a fractionated blood sample.

7. The method of claim 1 , wherein said measuring is effected using a method selected from the group consisting of flow cytometry, radioimmunoassay, immunofluorescence assay and enzyme-linked immunosorbent assay.

8. The method of claim 1 , further comprising depleting said sample of red blood cells prior to step (a).

9. The method of claim 1 , further comprising permeabilizing the blood sample prior to step (a).

10. The method of claim 1 , wherein said sample has been stored at 4° C. for no more than four hours.

11. The method of claim 1 , wherein said blood sample comprises granulocytes.

Assignments (2)
SECURITY INTEREST Recorded Mar 11, 2026
From: MEMED DIAGNOSTICS LTD.
To: WTI FUND X, INC.; WTI FUND XI, INC.
Reel/Frame 074048/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2011
From: EDAN, ERAN; OVED, KFIR
To: MEMED DIAGNOSTICS, LTD.
Reel/Frame 026624/0326 →
Continuity (2)
Provisional Application 61326244 · Apr 21, 2010
Related Publication 20110275542A1 · Nov 10, 2011